从标本兼治角度探讨补肾活血法调控OPG/RANKL/RANK/C-FOS与PPARγ/UCP1通路治疗绝经后骨质疏松的骨-脂代谢机制

中医学认为绝经后骨质疏松属于本虚标实之证，肾虚为本，血瘀为标，治宜标本兼治，补肾活血。藤黄健骨胶囊作为补肾活血法的代表方药，前期研究证实其具有抗骨质疏松作用，网络药理学研究也表明，藤黄健骨胶囊中的关键成分山奈酚等可能通过OPG/RANKL/RANK（骨代谢）和PPAR（脂代谢）等途径发挥治疗作用，但骨-脂代谢的相互作用机制尚不清楚。基于此，我们提出以下假说：藤黄健骨胶囊可能通过抑制OPG/RANKL/RANK/C-FOS和PPARγ/UCP1通路，且两条信号通路交互作用调节骨-脂代谢，发挥治疗作用。本项目拟用藤黄健骨胶囊干预去卵巢骨质疏松大鼠模型，检测其疗效；运用HE、ELISA、免疫组化、RT-PCR和Western Blot等方法检测OPG/RANKL/RANK/C-FOS及PPARγ/UCP1信号通路中关键分子的表达，为藤黄健骨胶囊多环节、多靶点、综合调节绝经后骨质疏松提供依据。

Traditional Chinese medicine believes that the postmenopausal osteoporosis was a virtual real standard of evidence, in this virtual kidney, the deficiency is in blood stasis. The main treatment method was treating both specimens and invigorating the kidney and promoting blood circulation. Tenghuang jiangu capsule as the representative prescription of tonifying kidney and promoting blood circulation, the previous studies shows that it has been proved to be effective in treating osteoporosis, the network pharmacology research also indicated that the kaempferol component of tenghuang jiangu capsule may play a therapeutic role through OPG/ RANKL/RANK (bone metabolism) and PPAR (lipid metabolism), but the mechanism of bone lipid interaction is not clear. Based on this, we proposed the following hypothesis: tenghuang jiangu capsule may play a role by inhibiting OPG/RANKL/RANK/C-FOS and PPAR γ/UCP1 signaling pathway and affecting the interaction of two signaling pathways regulates bone lipid metabolism. In this project, tenghuang jiangu capsule is proposed to be used to intervene the ovariectomized rats and its curative effect was tested. The expression of key molecules in OPG/RANKL/RANK/C-FOS and PPARγ/UCP1 signaling pathway was used to detect by HE, ELISA, immunohistochemistry, RT-PCR and Western Blot. The aim was to provide evidence for the comprehensive regulation of postmenopausal osteoporosis from multiple links and multiple targets of tenghuang jiangu capsule.